Filed with ASX · · 9 pages · English
Argent Biopharma Ltd has released its quarterly activity and cash flow report for the September quarter, detailing key operational updates and financial performance. The company is focusing on immune modulation and inflammatory diseases, with significant developments including licensing agreements for CannEpil® and antiviral products. Operating outflows for the quarter totaled a specific amount, with funding received through a convertible securities financing agreement. The report also includes a compliance statement confirming adherence to accounting standards and provides insights into the company's cash position.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
23 October 2026 September 2026 Quarterly Activity Report and Cash Flow Statement Argent Biopharma Ltd (ASX: RGT) is pleased to update the market for the September 2026 quarter, including material developments up to the date of this report, and attaches its Appendix 4C Quarterly Cash Flow report for...
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma